Company Overview - Tyligand Bioscience, established in 2017, is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies. The drug portfolio includes four candidate drugs, with the core product TSN1611 being a selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China, aimed at treating non-small cell lung cancer (NSCLC) [3][6]. Financial Information - The company reported revenues of RMB 7.856 million for the fiscal year 2024, RMB 1.506 million for the nine months ending September 30, 2024, and RMB 11.358 million for the nine months ending September 30, 2025 [5][6]. - The company incurred losses of approximately RMB 70.461 million for the fiscal year 2024, RMB 28.354 million for the nine months ending September 30, 2024, and RMB 123.406 million for the nine months ending September 30, 2025 [7]. - Gross profits were reported as RMB 7.121 million for the fiscal year 2024, RMB 1.506 million for the nine months ending September 30, 2024, and RMB 8.894 million for the nine months ending September 30, 2025 [8]. Industry Overview - Cancer is a leading cause of death globally, with approximately 10 million deaths annually. In 2024, there are expected to be 21.3 million new cancer cases, projected to rise to 27.1 million by 2035. In China, the most prevalent cancers are lung, colorectal, and thyroid cancers [9]. - The global oncology drug market has expanded significantly, with a market size growing from USD 150.3 billion in 2020 to USD 253.3 billion in 2024, reflecting a compound annual growth rate (CAGR) of 13.9%. It is expected to reach USD 702.7 billion by 2035, with immunotherapy being a major growth driver [9]. - The Chinese oncology drug market has also seen rapid growth, increasing from RMB 197.5 billion in 2020 to RMB 258.2 billion in 2024, with a CAGR of 6.9%. It is projected to reach RMB 1.04 trillion by 2035, with immuno-oncology drugs expected to capture a significant market share [12].

Group 1 - Tyligand Bioscience Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1][3] - The company, established in 2017, is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative cancer therapies [1] - Tyligand's drug portfolio includes four candidate drugs, with the core product TSN1611 being a highly selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China [1] Group 2 - TSN1611 targets KRAS G12D, one of the most common oncogenic driver mutations, which has historically been challenging to treat [1] - The company plans to advance TSN1611 into pivotal registration clinical trials for non-small cell lung cancer (NSCLC) in China [1] - Additional candidates in the pipeline include TSN222, a Phase 2 clinical candidate, and two preclinical candidates, TSNA1789 and TSNA3399 [1]

Group 1 - Tyligand Bioscience Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [1][3] - The company, established in 2017, is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative cancer therapies [1] - Tyligand's drug portfolio includes four candidate drugs, with the core product TSN1611 being a selective oral KRAS G12D inhibitor currently in Phase 2 clinical trials in the US and China [1] Group 2 - TSN1611 targets the KRAS G12D mutation, which is one of the most common oncogenic driver mutations and has historically been challenging to treat [1] - The company plans to advance TSN1611 into pivotal registration clinical trials in China for the treatment of non-small cell lung cancer (NSCLC) [1]

证券代码：688278 证券简称：特宝生物 公告编号：2026-008 厦门特宝生物工程股份有限公司 关于获得第九批国家级制造业单项冠军企业认定的 自愿性披露公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 一、基本情况 厦门特宝生物工程股份有限公司（以下简称"公司"）于近日获得工业和信息化部颁发的《制造业单项冠 军企业证书》，公司凭借聚乙二醇干扰素α-2b注射液（商品名：派格宾）的产品技术优势和市场地位被 认定为工业和信息化部第九批制造业单项冠军企业。 二、对公司的影响 制造业单项冠军企业是指长期专注于制造业特定细分领域，生产技术或工艺水平国际先进，单项产品 （生产性服务）市场占有率位居全球或国内前列的企业，是制造业竞争力的重要体现，也是加快发展新 质生产力的中坚力量。 公司以临床需求为导向，聚焦免疫和代谢领域拓展战略布局，持续提升创新研发能力。派格宾是公司自 主研发的全球首个40kD聚乙二醇长效干扰素α-2b注射液，是治疗用生物制品国家1类新药，也是我国第 一个国产上市的聚乙二醇（PEG）修饰干扰素品种。派格宾于20 ...

Core Viewpoint - The company, Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., forecasts significant growth in revenue for the year 2025, alongside a reduction in research and development expenses, while still expecting a net loss that is less severe than the previous year [2][7]. Group 1: Performance Forecast - The company anticipates 2025 annual revenue between 209.45 million and 250.88 million yuan, representing an increase of 179.35 million to 220.78 million yuan compared to the previous year, with a year-on-year growth rate of 595.96% to 733.62% [2]. - Expected R&D expenses for 2025 are projected to be between 425.21 million and 519.70 million yuan, a decrease of 90.09 million to 184.58 million yuan from the previous year, reflecting a year-on-year reduction of 14.77% to 30.27% [2]. - The forecasted net loss attributable to the parent company for 2025 is estimated to be between 480.64 million and 587.45 million yuan, which is a reduction of 209.83 million to 316.64 million yuan compared to the previous year, indicating a year-on-year decrease of 26.32% to 39.71% [2]. - The net loss attributable to the parent company after deducting non-recurring gains and losses is expected to be between 523.63 million and 630.44 million yuan, with a reduction of 173.89 million to 280.70 million yuan compared to the previous year, reflecting a year-on-year decrease of 21.62% to 34.90% [2]. Group 2: Previous Year Performance - In 2024, the company achieved a revenue of 30.10 million yuan [3]. - The R&D expenses for 2024 were recorded at 609.79 million yuan [4]. - The net loss attributable to the parent company for 2024 was 797.27 million yuan [5]. - The net loss attributable to the parent company after deducting non-recurring gains and losses for 2024 was 804.33 million yuan [6]. Group 3: Reasons for Performance Changes - The significant increase in revenue is attributed to the steady growth in sales of the company's first commercial product, the Saliqi monoclonal antibody injection, and the recognition of licensing income from the GR1803 injection licensing agreement [7]. - The company has maintained high levels of R&D investment while advancing multiple projects into clinical research stages, with core products entering critical clinical trial phases. The absence of share-based payment expenses in 2025, due to the completion of the stock incentive plan for the core team in 2024, has also contributed to the reduction in expenses [7].

Group 1 - The company anticipates a total profit loss of 291.82 million yuan for the year 2025, with a net profit attributable to the parent company expected to be -292.20 million yuan, and a net profit after deducting non-recurring gains and losses projected at -304.41 million yuan [3] - The expected operating revenue for 2025 is 37.25 million yuan, which is below 100 million yuan [3] - The company reported a total profit loss of 240.20 million yuan for the year 2024, with a net profit attributable to the parent company also at -240.20 million yuan [5] Group 2 - The significant changes in performance for 2025 are primarily influenced by the intensity of research and development (R&D) investment and the composition of revenue [7] - The company is advancing multiple core clinical projects, including D-0502, D-2570, and D-0120, which are in various stages of clinical trials [7] - The company has made key progress in its preclinical pipeline with two innovative candidates, YF087 and YF550, showing promising anti-tumor potential [7][8] Group 3 - The company maintains high levels of R&D investment, but its current revenue mainly comes from licensing and collaboration, which varies from year to year [8] - The income from technology licensing and collaboration is currently insufficient to cover costs and expenses, leading to expected continued losses in 2025 [8] - Despite the anticipated losses, the company's core business and competitive strengths have not experienced significant adverse changes [8]

Core Viewpoint - The resignation of the president of Kanghua Biological, Wu Hongbo, is speculated to be linked to the company's significant decline in performance, with a projected net profit drop for 2025 compared to the previous year [2][3]. Company Performance - Kanghua Biological's latest performance forecast indicates a net profit attributable to shareholders for 2025 is expected to be between 191 million and 233 million yuan, a substantial decrease from 399 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be between 208 million and 230 million yuan, representing a year-on-year decline of 49.73% to 54.54% [2]. Reasons for Performance Decline - The decline in performance is attributed to two main factors: a decrease in vaccine sales revenue by approximately 11% due to industry policy adjustments and market competition, and the absence of overseas licensing income for the year 2025, which previously contributed significant profit [2][3]. - The company's product structure is overly reliant on a single product, the freeze-dried human rabies vaccine, which poses a risk as competition intensifies from other companies with similar products expected to be approved this year [3]. Control Change and Profit Guarantee - In July 2025, Kanghua Biological underwent a change in control, with the previous controlling shareholder transferring 21.91% of shares to Shanghai Wankexin Biological, resulting in a new controlling entity without an actual controller [3]. - A "profit guarantee agreement" was signed, stipulating that the company must achieve a total net profit of no less than 728 million yuan from 2025 to 2026, or compensate the acquirer for any shortfall [3][4]. Future Prospects - To address the dual challenges of performance guarantees and product singularity, Kanghua Biological is focusing on new product development, including the initiation of clinical trials for a new six-valent norovirus vaccine [4].

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved net sales of EUR 11.3 billion, reflecting a growth of 13.3% year-over-year [6][12] - For the full year 2025, total sales reached EUR 43.6 billion, representing a 9.9% growth at constant exchange rates, which is at the upper end of the guidance [14][15] - Business EPS growth was strong at 26.7%, indicating effective operational leverage [12] - Business gross margin expanded by 1.8 percentage points to 77.5%, driven by a favorable product mix and operational efficiencies [14] Business Line Data and Key Metrics Changes - Newly launched medicines and vaccines generated EUR 5.7 billion in sales, with a growth of 34% in 2025 [4][6] - Dupixent sales reached EUR 4.2 billion in Q4 and EUR 15.7 billion for the full year, with over 30% increase in patient numbers [7][8] - Beyfortus sales grew by 9.5% to EUR 1.8 billion, driven by geographic expansion [8][9] Market Data and Key Metrics Changes - The company maintained leadership in influenza and RSV vaccines, with full-year sales of EUR 7.9 billion [8] - The U.S. market share for influenza vaccines increased, particularly with Fluzone High-Dose and Flublok [8] - Beyfortus has protected over 11 million babies in more than 45 countries, preventing an estimated 200,000 hospitalizations [9] Company Strategy and Development Direction - The company is transitioning into an R&D-driven, AI-powered biopharma entity, focusing on business development and M&A opportunities [4] - Strategic acquisitions, including Vicebio and Dynavax Technologies, are aimed at enhancing the vaccine portfolio and expanding into older adult markets [9][10][17] - The company plans to continue investing in manufacturing capacity to meet growing patient demand [14] Management's Comments on Operating Environment and Future Outlook - Management expects 2026 to deliver high single-digit growth in sales and business EPS to grow slightly faster than sales [18] - The company anticipates a decline in vaccine sales in 2026 but expects gross margin expansion to continue [18] - Management highlighted the importance of maintaining a strong capital structure and financial flexibility for future growth opportunities [16] Other Important Information - The company completed a EUR 5 billion share buyback program and proposed a 5% increase in dividends for the 31st consecutive year [17] - The company aims for a free cash flow of at least 20% of net sales in the medium term, with a strong cash flow generation of EUR 8.1 billion in 2025 [15] Q&A Session Summary Question: Can you elaborate on the Dupixent rollout and its competition? - Management reported strong performance with 25% growth year-over-year for Dupixent, driven by new indications like CSU and COPD [30][31] - The penetration rates for Dupixent in AD and CSU are still low, indicating room for market growth [32] Question: What is the outlook for Beyfortus in 2026? - Beyfortus had a 9% increase in 2025, with expectations for continued geographic expansion [34][35] Question: What are the prospects for Amlitelimab? - Management remains confident in Amlitelimab's potential, emphasizing its novel mechanism and the importance of data-driven decisions [39][41] Question: Can you provide details on the Kaposi sarcoma case related to Amlitelimab? - Management clarified that Kaposi sarcoma is associated with herpes virus and is not considered a significant concern for Amlitelimab [46][49] Question: What is the capital allocation strategy moving forward? - The company plans to dynamically allocate resources based on value, with an increase in business development activity expected [60][75]

Core Viewpoint - The company, Nocera Biopharma, announced that it expects to achieve profitability for the first time in 2025, with a projected net profit of approximately 633 million yuan, an increase of about 1.074 billion yuan compared to the same period last year [1] Financial Performance - The company anticipates total operating revenue of approximately 2.365 billion yuan in 2025, representing a growth of around 134% compared to the previous year [1]

（文章来源：证券日报） 证券日报网讯 1月29日，康泰生物发布公告称，公司预计2025年归属于上市公司股东的净利润为4900万 元至7300万元，同比下降75.70%至63.80%。 ...